Obesity and Diabetes

Genaera Corporation Presents New Preclinical Data for Obesity Compound Trodusquemine (MSI-1436) at CBI Conference

Published in Obesity and Diabetes Week, August 13th, 2007

Genaera Corporation (NASDAQ:GENR) announced new data from preclinical studies of trodusquemine (MSI-1436) for the treatment of obesity. Michael McLane, Ph.D., Vice President, Nonclinical Development, presented "Trodusquemine: A Novel Small Molecule for the Treatment of Obesity and Related Metabolic Disorders," during the CBI 3rd Annual Obesity Drug Development Summit, July 26-27 in Arlington, Va.

The presentation summarized results from preclinical studies demonstrating that MSI-1436 is a potent, highly-selective and reversible inhibitor of PTP-1B, an enzyme central to the function of both the leptin and insulin pathways. The mechanism of this inhibition, as indicated...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week

Source: Obesity and Diabetes Week (2007-08-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry